From the Journals

BTX Injections Appear Safe for Refractory Digital Ischemia in Systemic Sclerosis

Botulinum toxin injections show strong safety and efficacy as an adjunctive treatment for refractory digital ischemia, ulcers, and gangrene in patients with systemic sclerosis, according to a new JAMA Dermatology meta-analysis.

Share

  • 1

    Systemic sclerosis (scleroderma) affects skin and organs.

  • 2

    Approximately 300,000 Americans are diagnosed.

  • 3

    BTX injections shown to help with ischemic digital complications.

  • 4

    High response rates: ischemia (93.1%), ulcers (90.1%), gangrene (87.5%).

  • 5

    Adverse effects are minimal and often transient.

  • 6

    Younger age linked to faster response; prospective trials required.

  • 7

    Study featured in JAMA Dermatology.

Original Source(s)

BTX Injections Appear Safe for Refractory Digital Ischemia in Systemic Sclerosis

Botulinum toxin injections show strong safety and efficacy as an adjunctive treatment for refractory digital ischemia, ulcers, and gangrene in patients with systemic sclerosis, according to a new JAMA Dermatology meta-analysis.

  • by Jo Cavallo

  • December 15, 2025

  • 3 min

Related Content

Apocrine Gland Changes in Early Hidradenitis Suppurativa

Patient Insights on HRQOL in Chronic GVHD

Explore how cutaneous graft-versus-host disease impacts patients’ quality of life across physical, psychological, and social domains.

Alopecia Areata Linked to Mental, Autoimmune Risks